Description
The purpose of the funding will be to support a feasibility assessment and detailed engineering design for the expansion of Therapure’s current mammalian cell culture (MCC) capacity in support of VBI’s coronavirus vaccine as well as other M…
Amendment chain · 2 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $2,103,150 at start, $2,103,150 after amendment #2 (+$0).
- #02020-11-01$2,103,150
- #22021-06-28$2,103,150
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-11-01(start date) | $2,103,150 | — | The purpose of the funding will be to support a feasibility assessment and detailed engineering design for the… |
| #2 amendment | 2021-06-28 | $2,103,150 | +$0 | The purpose of the funding will be to support a feasibility assessment and detailed engineering design for the… |
Related records · 6
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 720950070)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 033-2021-2022-Q1-816022 | Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada · SIF Stream 2 - Growth | $93,848,000 | FY2022 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q3-959304 · retrieved 2026-11-12.